| Literature DB >> 30176889 |
Huan Jiang1, Xiao-Yi Yang2, Wei-Jie Zhu3.
Abstract
BACKGROUND: Tyrosine kinase receptor erythropoietin-producing hepatocellular receptor A2 (EphA2) is abundant in the endometrium and plays a role in the establishment of eutopic implantation. A similar molecular mechanism may exist between uterine implantation and tubal implantation, therefore EphA2 involvement in tubal pregnancy is suspected. Due to the limited availability of human Fallopian tube specimens, EphA2 expression in human Fallopian tube epithelium remains largely unknown.Entities:
Keywords: Cell adhesion; EphA2; Fallopian tube; Pregnancy; Receptor; Tubal
Mesh:
Substances:
Year: 2018 PMID: 30176889 PMCID: PMC6122472 DOI: 10.1186/s12958-018-0403-5
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Fig. 1EphA2 immunostaining (brown) on the Fallopian tube epithelium during normal menstrual cycle. a EphA2 was expressed on the apical membrane (triangle) and in the cytoplasm (arrow) of the tubal epithelial cells, including the ciliated cells and the secretory cells, while the staining intensities in the cytoplasm were weaker than those on the apical membranes. There was no staining evident in the interstitial cells. b EphA2 was present in the cilia of the ciliated cells (arrow). c Stronger stains were shown on the apical membranes of the tubal epithelial cells. d Negative control
EhpA2 expressions in human Fallopian tube epithelia
| Menstrual cycle phases | Exact menstrual cycle days | N | The Fallopian tube sites | ||
|---|---|---|---|---|---|
| Isthmus | Ampulla | infundibulum | |||
| Early-stage of proliferative phase | Days 1–5 | 8 | 4.57 ± 2.38 | 6.15 ± 2.23 | 5.16 ± 2.47 |
| Mid- and late-stages of proliferative phase | Days 7–14 | 6 | 6.43 ± 3.02 | 7.02 ± 3.15 | 6.29 ± 2.36 |
| Early-stage of secretive phase | Days 15–18 | 7 | 6.57 ± 3.29 | 6.54 ± 3.07 | 6.21 ± 2.98 |
| Mid- and late-stages of secretive phase | Days 19–28 | 8 | 5.43 ± 2.59 | 5.91 ± 2.54 | 5.73 ± 2.65 |
Positive unit (PU) values were determined by immunohistochemistry technique, and data were presented as mean ± standard deviation (SD). P > 0.05, compared between the two groups in the same line
Fig. 2EphA2 immunostaining (brown) on the Fallopian tube epithelium during tubal pregnancy. a EphA2 was present in the epithelial cells located in the implantation site of tubal pregnancy (arrow). b EphA2 was present in trophoblast cells found in the implantation site (arrow). c EphA2 was present in the non-implantation site of tubal pregnancy, and a stronger staining was evident on the cytomembrane (arrow) than that in the cytoplasm. d EphA2 expressions on the Fallopian tube epithelia with tubal pregnancy (n = 17) and the secretory Fallopian tube epithelia of normal controls (n = 15). EphA2 expression in the implantation group presented with the highest-level, compared with that in the non-implantation group and the control group (P < 0.05). EphA2 expressions in the latter two groups did not differ (P > 0.05)
Fig. 3Comparisons of EphA2 and Pho-EphA2 protein expression between the samples derived from the normal Fallopian tubes of the secretory phase (control) (n = 12) and the tubal pregnant tissues, which were further divided into the implantation group (n = 14) and the non-implantation group (n = 14). a Western blot showed positive bands of EphA2 and Pho-EphA2 in both the implantation and non-implantation groups of tubal pregnancy. b The highest EphA2 accompanied by the lowest Pho-EphA2 was detected in the implantation group, compared with that in the non-implantation group and the control group (P < 0.05). EphA2 and Pho-EphA2 protein expressions in samples of the latter two groups were similar (P > 0.05)
Fig. 4EphA2 mRNA levels did not differ among the control group (n = 12), the implantation group (n = 14) and the non-implantation group (n = 14) (P > 0.05)